Global Atopic Dermatitis (Atopic Eczema) Treatment Market Growth Opportunities, Consumptions, Industry Analysis and Forecasts 2025
Global Atopic Eczema treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness
(EMAILWIRE.COM, November 20, 2018 ) Global Atopic Dermatitis (Atopic Eczema) Treatment market 2018 is estimated to have a potential growth in the years to come due to the upcoming technology, which is improving and optimising the business processes.
Download Free PDF Sample of Global Atopic Dermatitis (Atopic Eczema) Treatment Market 2018 report @ http://decisionmarketreports.com/request-sample?productID=858821
Atopic Dermatitis Treatment Market
Atopic dermatitis is also known as atopic eczema. Atopic dermatitis is a type of inflammatory disease which is of unknown origin usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental exposure and difficulties in permeability of skin. Multiple factors such as seasonal allergies, low humidity, exposure to harsh detergents & soaps, and cold weather can trigger or worsen atopic dermatitis, including. The atopic dermatitis treatment includes mainly steroid creams and moisturizers. Often, antibiotics are used when there is a skin infection. Diagnosis is done by physical examination and in some cases, biopsy is performed. Atopic Dermatitis Treatment aims to control inflammation and relieving itching.
Atopic dermatitis treatment market Drivers and Restraints
Global Atopic Eczema treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the market during the forecast period.
Atopic dermatitis treatment market is expected to grow at steady state during the forecast period. Market players are focusing on research and development to discover new drugs to treat atopic dermatitis. Several global and regional players competing for the market share. Companies adopting several strategies such as acquisitions, mergers and partnering with other players to withstand the competition and grow their market share. For instance, AstraZeneca has entered into an agreement with LEO Pharma A/S, for the global license to tralokinumab in skin diseases.
Tralokinumab is a potential new medicine that is being developed in phase II clinical trials for the treatment of patients with atopic dermatitis. In December 2016, Novartis acquired UK based Ziarco Group and expanded its R&D portfolio with once daily oral H4 receptor agonist, ZPL389, that is being developed for the treatment of atopic dermatitis. In addition, new classes of products are launched targeting atopic dermatitis other than the traditional classes such as corticosteroids. This gives the health care professionals to choose various alternatives. For instance, in February 2017, Pfizer got FDA approval for Eucris, a non-steroidal topical phosphodiesterase-4 inhibitor that is used for treatment of mild to moderate atopic dermatitis.
Request Methodology for Global Atopic Dermatitis (Atopic Eczema) Treatment Market 2018 @ http://decisionmarketreports.com/request-methodolgy?productID=858821
Atopic dermatitis treatment market has been segmented on the basis of drug type, route of administration, distribution channel and region
Based on drug type, market is segmented into
Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Phosphodiesterase type 4 (PDE-4) Inhibitors
Antibiotics
Antihistamines
Emollients
Based on route of administration, market is segmented into
Oral
Topical
Parenteral
Based on distribution channel, market is segmented into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geographically atopic dermatitis treatment market has been segmented into following regions Viz. North America, Latin America, Asia Pacific, Europe, and Middle East and Africa. North America dominates the market, expected to show notable growth rates owing to product launches, lifestyle changes, and early treatment adoption. According to the national eczema association in the U.S., 31.6 million people are living with eczema. Europe atopic dermatitis market is growing due to large research and development activities. The Asia Pacific market is expected to grow at a higher rate owing to rapid population growth, availability of large patient pool and changing lifestyle.
Access full report with TOC @ http://decisionmarketreports.com/market-reports/858821/atopic-dermatitis-atopic-eczema-treatment-market
Atopic dermatitis treatment market leaders include Leo Pharma A/S (Denmark), Velite Pharmaceutical (India), Nestlé S.A. (Galderma SA) (Switzerland), Pfizer Inc. (U.S.), Anacor Pharmaceutical Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S), Sanofi S.A. (France), Novartis AG (Switzerland), Bayer AG (Germany), Mylan N.V. (Meda Pharmaceuticals) (U.S.), Bristol-Myers Squibb (BMS) (U.S), and Allergan Plc. (Ireland) to name a few.
In March 2017, Dupixent(dupilumab), the first and only biologic medicine for the treatment of adults with moderate-to-severe atopic dermatitis, approved by U.S. Food and Drug Administration (FDA). This drug was developed by Sanofi and Regeneron Pharmaceuticals in collaboration.
Report Outline:
The report provides granular level information about the market size, regional market share and forecast from 2018-2023
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
About Us
Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.
At Decision Market Reports, we provide research data from our field research and key opinion leaders. We fulfill all the research needs straddling across several industry verticals using our vast repository of research reports. We extend our services to the organization of all the sizes and across all the markets and industries. Consulting projects at Decision Market Reports assist you in finding the potential and cost-effective publisher, who can fulfill your research requirements in the best possible way. With the huge network of publishers, Decision Market Reports helps you get maximum out of a research report in the least possible time.
Contact Us
Gasper James
304, S Jones Blvd,
Las Vegas,
NV 89107, USA
US Toll Free +18666051052
Email: sales@decisionmarketreports.com
Web: http://decisionmarketreports.com/
Download Free PDF Sample of Global Atopic Dermatitis (Atopic Eczema) Treatment Market 2018 report @ http://decisionmarketreports.com/request-sample?productID=858821
Atopic Dermatitis Treatment Market
Atopic dermatitis is also known as atopic eczema. Atopic dermatitis is a type of inflammatory disease which is of unknown origin usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental exposure and difficulties in permeability of skin. Multiple factors such as seasonal allergies, low humidity, exposure to harsh detergents & soaps, and cold weather can trigger or worsen atopic dermatitis, including. The atopic dermatitis treatment includes mainly steroid creams and moisturizers. Often, antibiotics are used when there is a skin infection. Diagnosis is done by physical examination and in some cases, biopsy is performed. Atopic Dermatitis Treatment aims to control inflammation and relieving itching.
Atopic dermatitis treatment market Drivers and Restraints
Global Atopic Eczema treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the market during the forecast period.
Atopic dermatitis treatment market is expected to grow at steady state during the forecast period. Market players are focusing on research and development to discover new drugs to treat atopic dermatitis. Several global and regional players competing for the market share. Companies adopting several strategies such as acquisitions, mergers and partnering with other players to withstand the competition and grow their market share. For instance, AstraZeneca has entered into an agreement with LEO Pharma A/S, for the global license to tralokinumab in skin diseases.
Tralokinumab is a potential new medicine that is being developed in phase II clinical trials for the treatment of patients with atopic dermatitis. In December 2016, Novartis acquired UK based Ziarco Group and expanded its R&D portfolio with once daily oral H4 receptor agonist, ZPL389, that is being developed for the treatment of atopic dermatitis. In addition, new classes of products are launched targeting atopic dermatitis other than the traditional classes such as corticosteroids. This gives the health care professionals to choose various alternatives. For instance, in February 2017, Pfizer got FDA approval for Eucris, a non-steroidal topical phosphodiesterase-4 inhibitor that is used for treatment of mild to moderate atopic dermatitis.
Request Methodology for Global Atopic Dermatitis (Atopic Eczema) Treatment Market 2018 @ http://decisionmarketreports.com/request-methodolgy?productID=858821
Atopic dermatitis treatment market has been segmented on the basis of drug type, route of administration, distribution channel and region
Based on drug type, market is segmented into
Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Phosphodiesterase type 4 (PDE-4) Inhibitors
Antibiotics
Antihistamines
Emollients
Based on route of administration, market is segmented into
Oral
Topical
Parenteral
Based on distribution channel, market is segmented into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geographically atopic dermatitis treatment market has been segmented into following regions Viz. North America, Latin America, Asia Pacific, Europe, and Middle East and Africa. North America dominates the market, expected to show notable growth rates owing to product launches, lifestyle changes, and early treatment adoption. According to the national eczema association in the U.S., 31.6 million people are living with eczema. Europe atopic dermatitis market is growing due to large research and development activities. The Asia Pacific market is expected to grow at a higher rate owing to rapid population growth, availability of large patient pool and changing lifestyle.
Access full report with TOC @ http://decisionmarketreports.com/market-reports/858821/atopic-dermatitis-atopic-eczema-treatment-market
Atopic dermatitis treatment market leaders include Leo Pharma A/S (Denmark), Velite Pharmaceutical (India), Nestlé S.A. (Galderma SA) (Switzerland), Pfizer Inc. (U.S.), Anacor Pharmaceutical Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S), Sanofi S.A. (France), Novartis AG (Switzerland), Bayer AG (Germany), Mylan N.V. (Meda Pharmaceuticals) (U.S.), Bristol-Myers Squibb (BMS) (U.S), and Allergan Plc. (Ireland) to name a few.
In March 2017, Dupixent(dupilumab), the first and only biologic medicine for the treatment of adults with moderate-to-severe atopic dermatitis, approved by U.S. Food and Drug Administration (FDA). This drug was developed by Sanofi and Regeneron Pharmaceuticals in collaboration.
Report Outline:
The report provides granular level information about the market size, regional market share and forecast from 2018-2023
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
About Us
Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.
At Decision Market Reports, we provide research data from our field research and key opinion leaders. We fulfill all the research needs straddling across several industry verticals using our vast repository of research reports. We extend our services to the organization of all the sizes and across all the markets and industries. Consulting projects at Decision Market Reports assist you in finding the potential and cost-effective publisher, who can fulfill your research requirements in the best possible way. With the huge network of publishers, Decision Market Reports helps you get maximum out of a research report in the least possible time.
Contact Us
Gasper James
304, S Jones Blvd,
Las Vegas,
NV 89107, USA
US Toll Free +18666051052
Email: sales@decisionmarketreports.com
Web: http://decisionmarketreports.com/
Contact Information:
Decision Market Reports
Gasper James
Tel: +18666051052
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Decision Market Reports
Gasper James
Tel: +18666051052
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results